Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript Summary
Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript Summary
Operating expenses increased by 29% year-over-year, primarily due to investments in sales and marketing to boost lung diagnostic testing growth.The following is a summary of the Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript:
以下是biodesix公司（BDSX）2024年第三季度业绩会交流摘要：
Financial Performance:
金融业绩：
Biodesix reported Q3 revenue of $18.2 million, a 35% year-over-year increase, with lung diagnostic testing generating $17.2 million from 13,900 tests.
Gross margins were reported at 77%, indicating consistent high performance.
Operating expenses increased by 29% year-over-year, primarily due to investments in sales and marketing to boost lung diagnostic testing growth.
The net loss for the quarter improved by 6%, amounting to $10.3 million.
The company remains on track to meet its full-year 2024 revenue guidance of $70 million to $72 million and expects adjusted EBITDA profitability in the second half of 2025.
biodesix报告第三季度营业收入为1820万美元，同比增长35%，其中来自13900项测试的肺部诊断测试带来了1720万美元的收入。
毛利率报告为77%，表明持续高性能。
营业费用同比增长29%，主要是由于投资于销售和营销以推动肺部诊断测试增长。
本季度净损失改善了6%，达到1030万美元。
公司仍然按计划实现2024年全年营收指引为7000万至7200万美元，并预计在2025年下半年实现调整后的EBITDA盈利能力。
Business Progress:
业务进展：
The company added new coverage policies for Nodify X2 lung diagnostic tests, enhancing payer coverage.
Biodesix presented new data at the CHEST annual meeting, supporting the adoption of Nodify lung tests.
There was a focus on continuous investment in clinical excellence and new studies like CLARIFY to boost test adoption.
The biopharma services saw a contract growth, with $11.1 million in contracted but unrecognized revenue, promising revenue flows in the upcoming periods.
该公司为Nodify X2肺部诊断测试增加了新的保险政策，增强了支付者的覆盖范围。
biodesix在CHESt年会上发布了新数据，支持Nodify肺部测试的采用。
着重于持续投资于临床卓越性和诸如CLARIFY之类的新研究，以促进测试的采用。
生物制药服务业务签约增长，合同但未确认的营业收入达到1110万美元，预示着未来时期的营业收入将有所增加。
Opportunities:
机会：
The company is poised for future growth with an increasing number of coverage policies and clinical data supporting the lung diagnostic tests.
Ongoing and upcoming clinical studies (e.g., CLARIFY) and conferences (e.g., CHEST) present opportunities to bolster credibility and adoption of Biodesix's tests.
该公司凭借不断增加的覆盖政策数量和临床数据的支持，为未来增长做好准备。
正在进行和即将进行的临床研究（例如CLARIFY）和会议（例如CHEST）为增强Biodesix测试的可信度和采用提供了机会。
Risks:
风险：
Natural disasters like hurricanes impacted sales in the Southeast, demonstrating environmental risks that could affect operations and sales.
Delays in biopharma project completions underscore operational risks linked to timing and execution that could influence financial performance.
类似飓风这样的自然灾害影响了东南部地区的销售，展示了可能影响业务和销售的环保母基风险。
生物制药项目完成延误凸显了与时间和执行相关的操作风险，可能影响财务绩效。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。
